Ron Levy, M.D.

Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine, Director of the Lymphoma Program, and former Chief of the Division of Oncology, at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute.

Dr. Levy led research, spanning more than two decades, focused on monoclonal antibodies and malignant lymphoma. He has used innovations in immunology and molecular biology to gain a better understanding of the initiation and progression of the malignant process. Dr. Levy was the first to successfully treat cancer with a monoclonal antibody, and he went on to help develop rituximab (Rituxan®) to treat patients with resistant low-grade lymphomas.

Dr. Levy is a member of the National Academy of Sciences and the Institute of Medicine. He received an undergraduate degree in biochemistry from Harvard University and an M.D. from Stanford University.